CONCLUSION: Sarcopenia is a negative prognostic factor for ER in CD patients treated with biologics.
Dig Liver Dis. 2023 Mar 14:S1590-8658(23)00482-6. doi: 10.1016/j.dld.2023.02.017. Online ahead of print.
ABSTRACT
BACKGROUND: Sarcopenia has been associated with poor prognosis in chronic diseases.
AIMS: To investigate the role of sarcopenia in predicting clinical and endoscopic outcomes in patients with Crohn’s disease (CD).
METHODS: Consecutive CD patients who started biologics between 2014 and 2020 and underwent abdominal magnetic resonance or computed tomography within 6 months from the beginning of the biological therapy were enroled. Sarcopenia was defined as Psoas Muscle Index (PMI) lower than 5.4 cm²/m² (men) and 3.56 cm²/m² (women). Univariate and multivariate analyses were used to evaluate whether sarcopenia could predict steroid-free clinical remission (SFCR), endoscopic remission (ER), hospitalisation and surgery after 12 months of therapy.
RESULTS: 358 patients were included. Sarcopenia was found in 18.2% of patients, and it was associated with a lower rate of ER (14.8% vs 47.7%; p = 0.002) after 12 months of therapy, while it was not associated with SFCR (65.1% vs 70.1%; p = 0.435), hospitalisation (9.2% vs 7.8%; p = 0.801) and surgery (3.1% vs 6.1%; p = 0.549). Sarcopenia was identified as a predictor of lack of ER (odds ratio [OR]=5.2; p = 0.006), as well as smoking (OR=2.5; p = 0.028) and perianal disease (OR=2.6; p = 0.020).
CONCLUSION: Sarcopenia is a negative prognostic factor for ER in CD patients treated with biologics.
PMID:36925319 | DOI:10.1016/j.dld.2023.02.017
English
Arabic
Russian
French
Chinese (Simplified)
Japanese
Portuguese
Spanish